Is Jenburkt Pharmaceuticals Ltd (524731) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company .

Is Jenburkt Pharmaceuticals Ltd (524731) undervalued or overvalued?

The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Jenburkt Pharmaceuticals Ltd (524731) share price return in the past 10 years?

Jenburkt Pharmaceuticals Ltd share price has appreciated 9.4% annually (CAGR) over the past ten years.

Is Jenburkt Pharmaceuticals Ltd (524731) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Jenburkt Pharmaceuticals Ltd (524731)?

Company share prices are keep on changing according to the market conditions. The current trading price of Jenburkt Pharmaceuticals Ltd (524731) on 08-May-2026 16:59:59 at 16:59 is 1162.95.

What is the market cap of Jenburkt Pharmaceuticals Ltd (524731)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 08-May-2026 at 16:59, the market cap of Jenburkt Pharmaceuticals stood at Rs. 513.24 Cr.

What is the P/E ratio of Jenburkt Pharmaceuticals?

The latest standalone P/E ratio of Jenburkt Pharmaceuticals as of 08-May-2026 is 14.78.

What is the P/B ratio of Jenburkt Pharmaceuticals Ltd (524731)?

The latest standalone P/B ratio of Jenburkt Pharmaceuticals Ltd (524731) as of 08-May-2026 is 2.60.

What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd (524731)?

The 52-week high of Jenburkt Pharmaceuticals Ltd (524731) is Rs. 1410.00 and the 52-week low is Rs. 944.00.

What is the TTM revenue of Jenburkt Pharmaceuticals Ltd (524731)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jenburkt Pharmaceuticals is Rs. 168.74 (Cr.).

Jenburkt Pharmaceuticals Ltd (524731) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Jenburkt Pharmaceuticals Ltd (524731)
Brand: Jenburkt Pharmaceuticals

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	40.2%	39.3%	42%	36.9%	25.7%	23.8%	26.9%	26.8%	26.3%	27.9%	-
Value Creation Index ⓘ	1.9	1.8	2.0	1.6	0.8	0.7	0.9	0.9	0.9	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	93.6	103	115	123	119	109	124	137	142	152	169
Sales YoY Gr.	-	10.4%	11%	7%	-3.1%	-8.1%	13.4%	10.3%	3.8%	6.9%	-
Adj EPS ⓘ	22.9	28.9	36.9	43.2	31.8	35.6	47.9	54.4	58.3	71.9	78.7
YoY Gr.	-	26.3%	27.7%	17%	-26.3%	11.8%	34.5%	13.6%	7.2%	23.2%	-
BVPS (₹) ⓘ	86.4	117.1	133.5	168.8	174.3	214.6	255.8	277.3	328.4	389.2	446.5
Adj Net Profit ⓘ	10.6	13.4	17	19.8	14.6	16.3	22	24	25.7	31.7	35
Cash Flow from Ops. ⓘ	7.8	10	16.2	13	15	19.5	9.3	17.1	8.1	27.9	-
Debt/CF from Ops. ⓘ	0.7	0.6	0	0.6	0.2	0.2	0.6	0.1	0	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.5%	5%	7%	6.9%
Adj EPS ⓘ	13.6%	17.7%	14.5%	23.2%
BVPSⓘ	18.2%	17.4%	15%	18.5%
Share Price	9.4%	19.9%	16%	15.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	28.9	28.4	29.3	28.6	18.6	18.3	20.4	20	19.3	20	18.8
Op. Profit Mgn % ⓘ	17.6	19.1	20.7	20.4	16.6	18.2	22	22.2	23.3	26.6	25.9
Net Profit Mgn % ⓘ	11.4	13	14.8	16.2	12.3	15	17.7	17.6	18.1	20.9	20.6
Debt to Equity ⓘ	0.1	0.1	0	0.1	0	0	0.1	0	0	0	0
Working Cap Days ⓘ	71	65	69	84	101	129	177	185	156	182	70
Cash Conv. Cycle ⓘ	38	37	39	56	71	62	46	41	45	42	48

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 14.49%

Sales growth is good in last 4 quarters at 11.27%

Return on Equity has declined versus last 3 years average to 18.80%

Sales growth has been subdued in last 3 years 6.96%

	Standalone	Consolidated
TTM EPS (₹)	78.7	-
TTM Sales (₹ Cr.)	169	-
BVPS (₹) ⓘ	446.5	-
Reserves (₹ Cr.) ⓘ	193	-
P/BV ⓘ	2.60	-
PE ⓘ	14.78	-

From the Market
52 Week Low / High (₹)	944.00 / 1410.00
All Time Low / High (₹)	1.80 / 1410.00
Market Cap (₹ Cr.)	513
Equity (₹ Cr.)	4.4
Face Value (₹)	10
Industry PE ⓘ	44.2

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	94	103	115	123	119	109	124	137	142	152
Operating Expenses ⓘ +	77	84	91	98	99	89	97	106	109	111
Manufacturing Costs	5	4	5	5	5	4	6	7	7	6
Material Costs	25	28	31	33	30	28	27	29	27	26
Employee Cost	21	25	28	31	37	32	36	39	42	46
Other Costs ⓘ	25	26	27	28	28	25	26	32	33	34
Operating Profit ⓘ	16	20	24	25	20	20	27	30	33	40
Operating Profit Margin (%)	17.6%	19.1%	20.7%	20.3%	16.6%	18.2%	22.0%	22.2%	23.3%	26.6%
Other Income ⓘ +	3	3	3	3	4	4	5	5	5	7
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	1	0	0	0	0	0
Depreciation ⓘ	2	2	2	1	2	2	2	2	2	3
Profit Before Tax ⓘ	17	20	25	27	21	22	30	33	35	44
Tax ⓘ	6	7	8	7	6	5	8	8	9	12
Profit After Tax	11	14	17	20	15	17	22	25	26	32
PAT Margin (%)	11.5%	13.1%	15.0%	16.1%	12.5%	15.1%	18.0%	18.0%	18.3%	21.1%
Adjusted EPS (₹)	23.2	29.1	37.5	43.1	32.4	36.0	48.6	55.8	58.9	72.7
Dividend Payout Ratio (%)	31.10%	27.90%	24%	23.60%	25%	28.40%	24.70%	25.80%	26%	24.80%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	40	54	61	77	80	98	117	122	145	172
Share Capital ⓘ	5	5	5	5	5	5	5	4	4	4
Reserves ⓘ	36	50	57	73	75	94	113	118	141	167
Debt +	5	6	0	7	3	4	6	2	0	2
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	5	6	0	7	3	4	6	2	0	2
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	3	6	4	7	5	5	7	6	6	8
Others Liabilities ⓘ	9	10	12	11	16	14	12	10	13	13
Total Liabilities ⓘ	58	76	78	103	104	120	143	141	164	195
Fixed Assets
Net Fixed Assets ⓘ +	12	11	10	10	12	11	11	10	10	15
Gross Block	26	25	26	27	31	32	33	34	34	40
Accumulated Depreciation	13	15	16	17	20	21	22	24	23	26
CWIP ⓘ	0	0	0	1	0	0	0	1	1	40
Investments ⓘ	1	2	5	5	4	7	8	11	17	21
Inventories	8	11	7	10	11	8	10	8	9	9
Trade Receivables	6	9	13	23	18	14	15	17	19	21
Cash Equivalents	30	42	41	52	58	57	49	54	79	25
Others Assets ⓘ	2	2	2	2	2	25	49	40	29	65
Total Assets ⓘ	58	76	78	103	104	120	143	141	164	195

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	10	16	13	15	19	9	17	8	28
PBT ⓘ	17	20	25	27	21	22	30	33	35	44
Adjustment ⓘ	-1	-1	-2	-2	-1	-2	-2	-2	-0	-3
Changes in Working Capital ⓘ	-3	-3	1	-5	1	5	-11	-6	-18	0
Tax Paid ⓘ	-6	-7	-8	-7	-5	-6	-8	-8	-8	-13
Cash Flow From Investing Activity ⓘ +	-0	-10	1	-11	-3	-19	-1	3	-1	-17
Capex	-2	-0	-0	-2	-4	-1	-3	-2	-3	-20
Net Investments	-0	32	-2	-11	-2	-21	-4	3	-4	-3
Others ⓘ	3	-41	3	3	2	4	5	2	6	5
Cash Flow From Financing Activity ⓘ +	-5	1	-18	-2	-11	-1	-6	-21	-7	-8
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0	-0	-0	-0	-1	-0	-0	-1	-0	-0
Dividend Paid ⓘ	-3	0	-7	-1	-9	0	-5	-5	-6	-7
Others ⓘ	-2	1	-11	-1	-2	-1	-1	-15	-1	-1
Net Cash Flow ⓘ	2	1	-1	0	1	-0	3	-1	0	3

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	29.28	28.55	29.75	28.54	18.89	18.49	20.66	20.53	19.43	20.25
ROCE (%)	40.17	39.26	41.99	36.9	25.73	23.83	26.89	26.8	26.28	27.85
Asset Turnover Ratio	1.6	1.56	1.49	1.36	1.15	0.97	0.94	0.96	0.93	0.84
PAT to CFO Conversion(x)	0.73	0.71	0.94	0.65	1	1.12	0.41	0.68	0.31	0.88
Working Capital Days
Receivable Days	25.30	25.80	34.30	52.70	62.50	53.20	43	42.90	46.80	48.40
Inventory Days	30.40	33	27.90	24.80	31.80	30.90	25.70	24.30	21.70	21
Payable Days	51.10	61.10	59.30	58.80	71.50	64.60	77.80	84.40	84.80	101.40

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where itâ€™s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes:

Consumer Division:

Nocal Tablets
Nocal Sachet
Nocal Granular

Pharmaceutical Division:

Anti-Arthritic
Antibiotics
Anti-Diabetic
Nutraceuticals
Anti-Inflammory Analgesics
Gastro Intenstinal
Dermatologicals
Aphrodisiac
Anti-Osteoporotic
Anti-Cough, Cold & Allergy
Anti-Ulcerants

Awards

2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Jenburkt Pharmaceuticals Ltd (524731) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Jenburkt Pharma Share Price